8-K: Silexion Therapeutics Appeals Nasdaq Delisting, Securities Continue Trading Amid Compliance Concerns

Silexion Therapeutics Corp has appealed a Nasdaq delisting notice for failing to meet minimum market value requirements, securing a temporary stay and continued trading of its shares and warrants.

Summary

• Silexion Therapeutics Corp (SLXN, SLXNW) received a delisting notice from Nasdaq on May 22, 2025, due to non-compliance with two listing rules.
• The deficiencies relate to not maintaining a minimum Market Value of Listed Securities (MVLS) of $50,000,000 and a minimum Market Value of Publicly Held Shares (MVPHS) of $15,000,000.
• These issues were initially reported on November 22, 2024, and the company failed to rectify them within the 180-day period that ended on May 19, 2025.
• On May 28, 2025, the company requested a hearing with the Nasdaq Hearings Panel, which has stayed the delisting process.
• As a result of the appeal, Silexion's ordinary shares and warrants will continue to trade on the Nasdaq Global Market under their existing symbols.
• As part of its appeal strategy, Silexion intends to apply to transfer its listing to the Nasdaq Capital Market, which requires meeting an Equity Standard of at least $2.5 million in shareholders' equity.
• The company may also request additional time from the Nasdaq Hearings Panel to meet the Equity Standard.

Sentiment

Score: 3

Explanation: The sentiment is largely negative due to the company's failure to meet Nasdaq listing requirements and the receipt of a delisting notice. While the appeal has temporarily stayed the delisting, significant uncertainty and risk remain regarding the company's ability to maintain its listing, even on a lower tier market.

Positives

• The company's request for a hearing has successfully stayed the delisting process, allowing its securities to continue trading on the Nasdaq Global Market.
• The company has a clear strategy to potentially transfer its listing to the Nasdaq Capital Market, which has lower equity requirements.

Negatives

• Silexion Therapeutics Corp failed to meet Nasdaq's minimum Market Value of Listed Securities ($50,000,000) and Market Value of Publicly Held Shares ($15,000,000) requirements.
• The company was unable to rectify these listing deficiencies within the 180-day compliance period provided by Nasdaq.
• The company received a formal delisting notice from Nasdaq, indicating a serious compliance issue.

Risks

• There is no assurance that the company's hearing and request for transfer to the Nasdaq Capital Market will be successful.
• There is no assurance that the company will successfully comply with the Equity Standard for listing on the Nasdaq Capital Market (requiring at least $2.5 million of shareholders' equity) within any extension period that may be granted.
• The company may not be granted additional time to achieve or maintain the required shareholders' equity for the Nasdaq Capital Market.

Future Outlook

Silexion Therapeutics plans to appeal Nasdaq's delisting determination at a hearing scheduled for June 26, 2025. The company intends to apply to transfer its listing to the Nasdaq Capital Market, contingent on meeting the Equity Standard of at least $2.5 million in shareholders' equity. There is no guarantee that the appeal or transfer will be successful, or that the company will be granted additional time to meet the required equity standard.

Management Comments

• The company 'intends to apply to transfer the listing of our securities to the Nasdaq Capital Market, subject to our meeting the Equity Standard for continued listing on that market, which requires us to have, among other things, at least $2.5 million of shareholders equity.'
• The company 'may also request from the Nasdaq Hearings Panel additional time to meet that Equity Standard.'

Industry Context

This announcement highlights the ongoing challenges smaller or developing companies face in maintaining compliance with stringent stock exchange listing requirements, particularly market capitalization and public float standards. Such delisting threats are common for companies that experience significant stock price declines or prolonged periods of low valuation, irrespective of their underlying business operations.

Stakeholder Impact

• Shareholders face significant uncertainty regarding the future listing status and liquidity of their investments, with potential for delisting if the appeal and transfer strategy are unsuccessful.
• Employees may face uncertainty regarding the company's long-term stability and access to capital markets.

Next Steps

• Attend a hearing at the Nasdaq Hearings Panel on June 26, 2025, regarding the delisting appeal.
• Apply to transfer the listing of securities to the Nasdaq Capital Market.
• Work towards meeting the Nasdaq Capital Market's Equity Standard of at least $2.5 million in shareholders' equity.
• Potentially request additional time from the Nasdaq Hearings Panel to meet the Equity Standard.

Key Dates

Recommendation

Keywords

Nasdaq delisting, listing compliance, Market Value of Listed Securities, Market Value of Publicly Held Shares, Nasdaq Capital Market, shareholders' equity, SEC filing, Silexion Therapeutics, SLXN, SLXNW